NCT04572399

UVA Light Device to Treat COVID-19

Completed NA Results posted Last updated 9 January 2025

What this trial tests

NA trial testing UV Light Treatment in Coronavirus in 5 participants. Completed in 28 December 2020.

Timeline

30 October 2020

Primary endpoint
28 December 2020

28 December 2020

Quick facts

Lead sponsor	Cedars-Sinai Medical Center
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	5
Start date	30 October 2020
Primary completion	28 December 2020
Estimated completion	28 December 2020
Sites	1 location across United States

Drugs / interventions tested

• UV Light Treatment

Conditions studied

• Coronavirus — all drugs for Coronavirus →

Sponsor

Cedars-Sinai Medical Center

Who can join

18 and older, any sex, with Coronavirus. Patients with the condition only — healthy volunteers not accepted.

Results — posted to ClinicalTrials.gov

Per-arm endpoint measurements with 95% confidence intervals where reported. Source: trial results section.

Negative Change in Viral Load Primary · 5 days

Change of viral load in upper airway in patients admitted to hospital for COVID-19

Group	Value	95% CI
Endotracheal UV Light	3.2	1.20 – 6.77

Change in Bacterial Load Secondary · 5 days

Change of bacterial load in upper airway

Group	Value	95% CI
Endotracheal UV Light	102000	± 594000

Ventilated Associated Pneumonia Secondary · 1 month

Percentage of patients developing ventilated pneumonia (VAP) within 30 days of treatment

Group	Value	95% CI
Endotracheal UV Light	1

Days to Extubation Secondary · 1 month

Number of days patient is intubated with endotracheal tube or tracheostomy

Group	Value	95% CI
Endotracheal UV Light	20.75	6 – 30

Days to Discharge Secondary · 1 month

Number of days patient is discharged from the hospital

Group	Value	95% CI
Endotracheal UV Light	27.25	19 – 30

Change in C-reactive Protein Secondary · 5 days

Change in C-reactive protein from baseline to the end of the treatment

Group	Value	95% CI
Endotracheal UV Light	95.00	± 48.00

Change in the World Health Organization (WHO) Coronavirus Disease (COVID)-19 10-point Ordinal Severity Scale by 30 Days Secondary · 1 month

The World Health Organization (WHO) COVID-19 10-point ordinal severity scale: 0 uninfected, No viral RNA detected 1. Asymptomatic; viral RNA detected 2. Ambulatory Mild disease: Symptomatic; independent 3. Ambulatory Mild disease: Symptomatic; assistance needed 4. Hospitalized: Moderate disease; no oxygen therapy 5. Hospitalized: Moderate disease; oxygen by mask or nasal prongs 6. Hospitalized: sever disease, Oxygen by non-invasive ventilation or high flow 7. Hospitalized: severe disease, intubation and mechanical ventilation, pO2/FiO2\>=150 or SpO2/FiO2\>=200 8. Hospitalized: severe disease

Group	Value	95% CI
Endotracheal UV Light	3.6	-1 – 7

Sponsor's own description

This pilot study will assess the safety and effectiveness of UV light treatment in hospitalized patients with COVID-19.

Publications & conference data

3 peer-reviewed publications reference this trial (live from Europe PMC):

1. Investigating the Potential for Ultraviolet Light to Modulate Morbidity and Mortality From COVID-19: A Narrative Review and Update.
   Gorman S, Weller RB. · · 2020 · cited 16× · PMID 33426009 · DOI 10.3389/fcvm.2020.616527
2. Endotracheal Application of Ultraviolet A Light in Critically Ill Patients with Severe Acute Respiratory Syndrome Coronavirus 2: A First-in-Human Study.
   Rezaie A, Melmed GY, Leite G, Mathur R, et al · · 2021 · cited 4× · PMID 34173969 · DOI 10.1007/s12325-021-01830-7
3. Endotracheal application of ultraviolet A light in critically ill severe acute respiratory syndrome coronavirus-2 patients: A first-in-human study
   Rezaie A, Melmed GY, Leite G, Mathur R, et al · · 2021 · DOI 10.1101/2021.03.05.21252997